YM-900

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526938

CAS#: 143151-35-3

Description: YM-900, also known as YM-90K, is an AMPA receptor antagonist and glutamate receptor antagonist potentially for the treatment of stroke.


Price and Availability

Size
Price

Size
Price

Size
Price

YM-900 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 526938
Name: YM-900
CAS#: 143151-35-3
Chemical Formula: C11H7N5O4
Exact Mass: 273.0498
Molecular Weight: 273.208
Elemental Analysis: C, 48.36; H, 2.58; N, 25.63; O, 23.42


Synonym: YM-90K; YM-900; YM90K; YM900; YM 90K; YM 900.

IUPAC/Chemical Name: 6-(1H-imidazol-1-yl)-7-nitro-1,4-dihydroquinoxaline-2,3-dione

InChi Key: GBWIZNYOJITVFI-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H7N5O4/c17-10-11(18)14-7-4-9(16(19)20)8(3-6(7)13-10)15-2-1-12-5-15/h1-5H,(H,13,17)(H,14,18)

SMILES Code: O=C1NC2=C(C=C(N3C=CN=C3)C([N+]([O-])=O)=C2)NC1=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Hashimoto T, Narikawa S, Huang XL, Minematsu T, Usui T, Kamimura H, Endou H. Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters. Drug Metab Dispos. 2004 Oct;32(10):1096-102. PubMed PMID: 15377641.

2: Iwasaki K, Chung EH, Egashira N, Hatip-Al-Khatib I, Mishima K, Egawa T, Irie K, Fujiwara M. Non-NMDA mechanism in the inhibition of cellular apoptosis and memory impairment induced by repeated ischemia in rats. Brain Res. 2004 Jan 2;995(1):131-9. PubMed PMID: 14644478.

3: Katsuta K, Umemura K, Ueyama N, Matsuoka N. Pharmacological evidence for a correlation between hippocampal CA1 cell damage and hyperlocomotion following global cerebral ischemia in gerbils. Eur J Pharmacol. 2003 Apr 25;467(1-3):103-9. PubMed PMID: 12706462.

4: Nakano M, Ueda H, Li JY, Matsumoto M, Yanagihara T. A potent AMPA/kainate receptor antagonist, YM90K, attenuates the loss of N-acetylaspartate in the hippocampal CA1 area after transient unilateral forebrain ischemia in gerbils. Life Sci. 2001 Sep 14;69(17):1983-90. PubMed PMID: 11589513.

5: Turski L, Schneider HH, Neuhaus R, McDonald F, Jones GH, Löfberg B, Schweinfurth H, Huth A, Krüger M, Ottow E. Phosphonate quinoxalinedione AMPA antagonists. Restor Neurol Neurosci. 2000;17(1):45-59. PubMed PMID: 11490077.

6: Stutzmann JM, Bohme GA, Boireau A, Damour D, Debono MW, Genevois-Borella A, Jimonet P, Pratt J, Randle JC, Ribeill Y, Vuilhorgne M, Mignani S. Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. Bioorg Med Chem Lett. 2001 May 7;11(9):1205-10. PubMed PMID: 11354378.

7: Nikam SS, Kornberg BE. AMPA receptor antagonists. Curr Med Chem. 2001 Feb;8(2):155-70. Review. PubMed PMID: 11172672.

8: Stutzmann JM, Bohme GA, Boireau A, Damour D, Debono MW, Genevois-Borella A, Imperato A, Jimonet P, Pratt J, Randle JC, Ribeill Y, Vuilhorgne M, Mignani S. 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7. PubMed PMID: 10843235.

9: Mignani S, Bohme GA, Boireau A, Cheve M, Damour D, Debono MW, Genevois-Borella A, Imperato A, Jimonet P, Pratt J, Randle JC, Ribeill Y, Vuilhorgne M, Stutzmann JM. 8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonists. Bioorg Med Chem Lett. 2000 Mar 20;10(6):591-6. PubMed PMID: 10741560.

10: Shirane M, Nakamura K. Group II metabotropic glutamate receptors are a common target of N-anisoyl-GABA and 1S,3R-ACPD in enhancing ACh release in the prefrontal cortex of freely moving SHRSP. Neuropharmacology. 2000 Mar 3;39(5):866-72. PubMed PMID: 10699452.

11: YM 900. YM 90K. Drugs R D. 1999 Jan;1(1):42-3. PubMed PMID: 10565984.

12: Kodama M, Yamada N, Sato K, Kitamura Y, Koyama F, Sato T, Morimoto K, Kuroda S. Effects of YM90K, a selective AMPA receptor antagonist, on amygdala-kindling and long-term hippocampal potentiation in the rat. Eur J Pharmacol. 1999 Jun 11;374(1):11-9. PubMed PMID: 10422635.

13: Shimojo M, Takasugi K, Yamamoto I, Funato H, Mochizuki H, Kohsaka S. Neuroprotective action of a novel compound--M50463--in primary cultured neurons. Brain Res. 1999 Jan 2;815(1):131-9. PubMed PMID: 9974133.

14: Arias RL, Tasse JR, Bowlby MR. Neuroprotective interaction effects of NMDA and AMPA receptor antagonists in an in vitro model of cerebral ischemia. Brain Res. 1999 Jan 23;816(2):299-308. PubMed PMID: 9878799.

15: Boireau A, Meunier M, Imperato A. Ouabain-induced increase in dopamine release from mouse striatal slices is antagonized by riluzole. J Pharm Pharmacol. 1998 Nov;50(11):1293-7. PubMed PMID: 9877317.

16: Takamatsu H, Kondo K, Ikeda Y, Umemura K. Neuroprotective effects depend on the model of focal ischemia following middle cerebral artery occlusion. Eur J Pharmacol. 1998 Dec 4;362(2-3):137-42. PubMed PMID: 9874163.

17: Li H, Matsumoto K, Watanabe H. An alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist and an N-methyl-D-aspartate (NMDA) channel blocker synergistically impair spatial memory in rats. Biol Pharm Bull. 1998 Nov;21(11):1228-30. PubMed PMID: 9853420.

18: Kawasaki-Yatsugi S, Ichiki C, Yatsugi S, Shimizu-Sasamata M, Yamaguchi T. YM90K, an AMPA receptor antagonist, protects against ischemic damage caused by permanent and transient middle cerebral artery occlusion in rats. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):586-91. PubMed PMID: 9840429.

19: Kawasaki-Yatsugi S, Shimizu-Sasamata M, Yatsugi S, Yamaguchi T. Delayed treatment with YM90K, an AMPA receptor antagonist, protects against ischaemic damage after middle cerebral artery occlusion in rats. J Pharm Pharmacol. 1998 Aug;50(8):891-8. PubMed PMID: 9751454.

20: Kohara A, Okada M, Tsutsumi R, Ohno K, Takahashi M, Shimizu-Sasamata M, Shishikura J, Inami H, Sakamoto S, Yamaguchi T. In-vitro characterization of YM872, a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist. J Pharm Pharmacol. 1998 Jul;50(7):795-801. PubMed PMID: 9720630.